AzTrials
AzTrials

Liver Transplant RejectionNCT04514666

VOCs in Kidney and Liver Transplants

A study testing Breath analysis in people with Liver Transplant Rejection and Kidney Transplant; Complications, run by Societa Italiana di Chirurgia ColoRettale at 1 site in Italy.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Kidney and liver trasplants represent very challenging lifesaving and effective surgical procedures for patients with end-stage kidney and/or liver disease. Chronic rejection may occur in 3 to 17% livers transplants and in 20 to 40% kidney transplants. Read more about this study

Who is it for?
Ages 18 to 75 years
What is being tested?
Breath analysis
Could I receive a placebo?
No, everyone receives an active treatment
How many people
100 participants
Where
1 siteItaly
Study dates
2 Oct 2021to 2 Mar 2023
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Both sex
  • Patients eligible for liver or kidney transplant
  • Written informed consent

Who cannot join

  • Acute liver failure
  • Acute liver and kidney rejection
  • HCC
  • Re-transplant
  • Pregnancy
  • IBD
  • Any psychiatric disease

Trial locations and contacts

1 site in 1 country.

Arcangelo Picciariello, MD contact

+393492185104

arcangelopicciariello@gmail.com

Italy1 site
  • Dept of Emergency and Organ transplantation

    Bari, 70124

    Arcangelo F Picciariello, MD, 00393492185104, arcangelopicciariello@gmail.com

    Arcangelo Picciariello, MD

Other trials in Italy

About this study

Official title: Exhaled Volatile Organic Compounds as Potential Predictive Biomarkers of Chronic Kidney and Liver Rejection After Transplants

Kidney and liver trasplants represent very challenging lifesaving and effective surgical procedures for patients with end-stage kidney and/or liver disease.

Chronic rejection may occur in 3 to 17% livers transplants and in 20 to 40% kidney transplants.

Read more

While acute rejection is clearly detected due to the clinical features and laboratory tools, the early identification of chronic rejection is still challenging since the clinical features are often silents and laboratory tests become suggestive when the damage due to the rejection is almost irreversible.

Considering the recent application of the breathomic to liver and kidney disease and the difficulty in the early detection of chronic rejection after liver and kidney transplants, the analysis of the exhaled VOCs pattern could help early detection of chronic rejection allowing a prompt medical treatment.

Read the detailed description

Kidney and liver trasplants represent very challenging lifesaving and effective surgical procedures for patients with end-stage kidney and/or liver disease.

Nowadays the short and long term success rate of kidney and liver trasplants is pretty hight. Nevertheless, transplant rejection remains one of the biggest limitations with a strong impact on patients survival.

Usually acute rejection occurs within 3 months after the transplant and is the most common cause of transplant failure and the most common indication for re-transplantation .

Chronic rejection may occur in 3 to 17% livers transplants and in 20 to 40% kidney transplants.

While acute rejection is clearly detected due to the clinical features and laboratory tools, the early identification of chronic rejection is still challenging since the clinical features are often silents and laboratory tests become suggestive when the damage due to the rejection is almost irreversible.

Chronic renal transplant rejection is the result of a gradual decrease in the kidney function that starts to become evident three months after surgery.

Kidney chronic rejection is, by definition, immune-mediated and generally divides into chronic active antibody-mediated rejection and chronic active T cell-mediated rejection.

Transplant vasculopathy is the single most important feature of chronic renal transplant rejection and it is the direct consequence of an immune reaction that activates a cytokines cascade with a tissue fibrosis and chronic rejection.

Hypertension and proteinuria are the most important features of declining renal function.

Laboratory tests such as serum creatinine and estimated glomerular filtration rate (eGFR)ccan help to early identify kidney allograft dysfunction. The eGFR is suggested to be a more accurate indicator and predictor of graft function and long term graft loss.

However, a biopsy is mandatory for diagnosing chronic renal transplant rejection. C4d complement fragment deposition in the peritubular capillaries represents the marker for antibody-mediated tissue injury.

Although the incidence of acute and chronic rejection has declined with improvement of immunosuppression regimens, chronic rejection may lead to re-transplant or death.

Chronic liver allograft rejection usually occurs more than 2 months after transplantation and most frequently develops after an unresolved or multiple episodes of acute rejection or indolently over a period of months to years, with few or no clinically apparent acute cellular rejection episodes.

Chronic rejection characterized primarily by fibrointimal hyperplasia of arteries, or obliterative arteriopathy, interstitial fibrosis and atrophy of parenchymal elements.

Often the only reliable early indicator of chronic rejection is persistent and preferential elevation of γ-glutamyl transpeptidase and alkaline phosphatase, which is related to bile duct damage. In most of cases the only clinical sign is jaundice and it appears when allograft dysfunction becomes. Biliary sludging or appearance of biliary strictures, hepatic infarcts, and finally loss of hepatic synthetic function, which can manifest as coagulopathy, malnutrition, and hepatosplenomegaly are late findings presaging allograft failure. Biopsy is mandatory to assess the liver damage.

Breath analysis (Breathomics) is applied widely nowadays in clinical setting in order to identify and evaluate exhaled molecular volatile compounds as expression of a metabolic derangement of the organism including chronic diseases and cancer disease.

A novel approach, a breath test based on the metabolomic evaluation of the volatile organic compounds (VOCs) in the exhaled breath, has recently been developed by our group to identify patients with Colorectal cancer, showing good reliability and compliance.

VOCs analysis has also been demonstrated to find an application in the diagnosis of chronic liver and kidney disease with high sensitivity and specificity.

Considering the recent application of the breathomic to liver and kidney disease and the difficulty in the early detection of chronic rejection after liver and kidney transplants, the analysis of the exhaled VOCs pattern could help early detection of chronic rejection allowing a prompt medical treatment.

Being tested
Breath analysis

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Breath analysisOther

    The breath of patients undergoing liver or kidney transplant will be sampled and volatile organic compounds will be identified

Study groups in NCT04514666
Study groupRoleWhat they receive
Liver/kidney transplantExperimentalThe breath of patients undergoing liver or kidney transplant will be sampled and analysed
Receives: Other: Breath analysis

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Volatile organic compounds in end stage liver disease

    to evaluate the pattern of volatile organic compounds in patients elegible for liver transplant

    Measured: 30 days

  2. Volatile organic compounds in end stage kidney disease

    to evaluate the pattern of volatile organic compounds in patients elegible for kidney transplant

    Measured: 30 days

  3. Volatile organic compounds after liver transplant

    to evaluate the pattern of volatile organic compounds able to identify the onset of chronic failure/rejection after liver transplants

    Measured: 1 year

  4. Volatile organic compounds after liver transplant

    to evaluate the pattern of volatile organic compounds able to identify the onset of chronic failure/rejection after kidney transplants

    Measured: 1 year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 Aug 2020
  2. Study start2 Oct 2021 (estimated)
  3. Primary completion2 Oct 2022 (estimated)
  4. Study completion2 Mar 2023 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
100 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04514666
Sponsor's protocol ID
38/2020
Status last verified
Apr 2021
First submitted
12 Aug 2020
Last updated
20 Apr 2021
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Breath analysis in people with Liver Transplant Rejection and Kidney Transplant; Complications, run by Societa Italiana di Chirurgia ColoRettale at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 20 Apr 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Arcangelo Picciariello, MD (+393492185104, arcangelopicciariello@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Volatile organic compounds in end stage liver disease (time frame: 30 days). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Apr 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in